• Resources
  • About
  • Events
    • Upcoming Events
    • Archived Events
  • The ORBCoN Report
  • Bloody Easy E-Tools & Publications
    • Bloody Easy Blood Administration (BEBA)
    • Bloody Easy for Healthcare Professionals
    • Bloody Easy Lite
    • ORBCoN Tech Assess
  • Blood Utilization & Audits
    • Audits Tools
    • Blood Utilization Graphs
    • COPTN Reports
    • O Negative RBC Utilization
    • Provincial Audit Reports
  • IVIG/SCIG
  • Massive Hemorrhage Protocol
    • eLearning
    • Provincial MHP Toolkit
    • Supplementary Resources
    • Recommendation Statements
  • ORBCoN Resources
    • Helpful Apps
    • The ORBCoN Report
    • Order Resources
    • Presentation Library
  • Toolkits
    • Bedside Audit
    • Dispensary and Administration
    • Emergency Blood Management
    • Home Infusion Toolkit
    • Implementing an Evaluation Process for your Transfusion Medicine Lab Competency Assessment Program (CAP)
    • Inventory Management
    • New Product
    • OTTRM
    • Resources for Midwives
    • Special Blood Requirements
    • Transporting Blood Internally
    • Transfusion Committee
    • Transfusion Safety Officer Resource Manual
    • Quality Improvement Plan
  • TM Guidelines, Standards, & Recommendations
    • Guidelines
    • NAC Guidelines and Recommendations
    • Recommendations
    • Resource Manual for Medical Directors of Transfusion Medicine
    • Standards
  • Quality Improvement
Home » IVIG/SCIG » Utilization Management Guidelines »

Antiphospholipid syndrome (other than catastrophic)

Do Not Use

For the following indications, there is insufficient or no evidence to support the use of IG. Alternatives to IG are often available.

RecommendationsIG is not recommended.
 
(see separate entry for Catastrophic Antiphospholipid Syndrome)
  • Utilization Management Guidelines

    Rheumatology

    • Antiphospholipid syndrome – catastrophic
    • Antiphospholipid syndrome (other than catastrophic)
    • Autoimmune retinopathy (AIR)
    • Behçet disease
    • Eosinophilic granulomatosis with polyangiitis (EGPA) (Churg–Strauss disease)
    • Idiopathic Inflammatory myopathy (IIM)
    • Inclusion body myositis (IBM)
    • Juvenile Idiopathic Inflammatory Myopathy (J-IIM)(Previously Juvenile Dermatomyositis)
    • Kawasaki Disease
    • Macrophage activation syndrome (MAS)
    • Multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2/COVID-19 infection
    • Rheumatoid arthritis

© 2025 Copyright: Ontario Regional Blood Coordinating Network

    • Contact
    • Order Resources
    • Careers
    • Useful Links
    • Privacy
    • Legal
Subscribe to our newsletter
    • Contact
    • Order Resources
    • Careers
    • Useful Links
    • Privacy
    • Legal
Subscribe to our newsletter

© 2025 Copyright: Ontario Regional Blood Coordinating Network